Discovery of novel cyclopentane carboxylic acids as potent and selective inhibitors of NaV1.7

Bioorg Med Chem Lett. 2025 Feb 1:116:130033. doi: 10.1016/j.bmcl.2024.130033. Epub 2024 Nov 22.

Abstract

Discovery efforts leading to the identification of cyclopentane carboxylic acid 31, a potent inhibitor of NaV1.7 that showed high selectivity over NaV1.5 and exhibited robust analgesic effects in an inherited erythromelalgia (IEM) transgenic mouse assay, are described herein. Key design elements that culminated in the discovery of 31 include exploration of proline substituents, replacement of the proline warhead with cyclopentane carboxylic acid, that led to significantly boosted NaV1.7 potency, and replacement of the metabolically labile adamantane motif with the 2,6-dichlorobenzyl substituted piperidine system, that addressed metabolic instability and led to a significant improvement in PK.

Keywords: Cyclopentane carboxylic acid; Na(V)1.7; Pain; Proline; Voltage-gated sodium channel.

MeSH terms

  • Animals
  • Carboxylic Acids* / chemical synthesis
  • Carboxylic Acids* / chemistry
  • Carboxylic Acids* / pharmacology
  • Cyclopentanes* / chemical synthesis
  • Cyclopentanes* / chemistry
  • Cyclopentanes* / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Discovery*
  • Humans
  • Mice
  • Mice, Transgenic
  • Molecular Structure
  • NAV1.7 Voltage-Gated Sodium Channel* / metabolism
  • Structure-Activity Relationship
  • Voltage-Gated Sodium Channel Blockers / chemical synthesis
  • Voltage-Gated Sodium Channel Blockers / chemistry
  • Voltage-Gated Sodium Channel Blockers / pharmacology

Substances

  • NAV1.7 Voltage-Gated Sodium Channel
  • Carboxylic Acids
  • Cyclopentanes
  • Voltage-Gated Sodium Channel Blockers